Sernova (PSH0) Price & Analysis

Compare

2 Followers

PSH0 Stock Chart & Stats

Day’s Range― - ―

52-Week Range€0.08 - €0.27

Previous CloseN/A

VolumeN/A

Average Volume (3M)8.41K

Market Cap

C$41.56M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.51

Next Earnings

Sep 24, 2025

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding328,484,770

10 Day Avg. Volume15,106

30 Day Avg. Volume8,414

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$2.09

Price Target Upside1639.86% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessSernova's Phase 1/2 study results are indicative of the trial being on track to succeed and help de-risk any upcoming data readouts and subsequent studies.

Patient Outcomes8 of 12 (66%) patients achieving insulin independence, thus far; a critical measure to highlight with investors.

Product DifferentiationSernova’s data remain highly competitive, with a delivery approach that is differentiated through its targeted, implantable Cell Pouch platform.

Bears Say

Competitive LandscapeDeep responses in diabetes patients position the technology for potential commercial success, particularly as competitors exit the space, and the impressive response rates and durability support Sernova's strategy and justify further investigation.

Interim DataDespite these data coming from an interim clinical evaluation, these are clear efficacy signals and the safety profile has remained favorable.

Sernova News

Sernova and Eledon Collaborate on Potential Type 1 Diabetes Cure

The latest update is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has announced a collaboration with Eledon...

23d ago

Promising Advancements and Strategic Partnerships Bolster Sernova’s Buy Rating for T1D Treatment

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova today and set a price target of...

24d ago

Sernova’s Promising T1D Treatment Strategy Gains Confidence with External Validation and Unique Cell Pouch System

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova (SVA – Research Report) today and set...

1M ago

Sernova Biotherapeutics Appoints Interim Chair Amid Strategic Advancements

Sernova ( ($TSE:SVA) ) has shared an announcement. Sernova Biotherapeutics has appointed its CEO, Jonathan Rigby, as the...

2M ago

Sernova Biotherapeutics Forms Clinical Advisory Board to Advance Diabetes Treatment

Sernova ( ($TSE:SVA) ) just unveiled an announcement. Sernova Biotherapeutics has announced the formation of a Clinical Advisory...

2M ago

Sernova’s Cell Pouch Shows Promising Results in Diabetes Trial

Sernova ( ($TSE:SVA) ) has provided an update. Sernova Biotherapeutics announced positive interim data from its ongoing Phase...

3M ago

Promising Interim Data from Sernova’s Cell Pouch Trial Boosts Stock Potential

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sernova (SVA –...

3M ago

Sernova Biotherapeutics Secures $4 Million Loan for Clinical Advancements

Sernova ( ($TSE:SVA) ) has issued an update. Sernova Biotherapeutics has secured a $4 million loan from Navigate...

3M ago

Sernova’s Promising Position in T1D Treatment: Buy Rating Affirmed by Joseph Pantginis

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Sernova (SVA – Research Report). The...

3M ago

Sernova’s Innovative Diabetes Treatment to be Featured at International Conference

Sernova ( ($TSE:SVA) ) has issued an announcement. Sernova Biotherapeutics announced that their Cell Pouch Bio-hybrid Organ, aimed...

4M ago

PSH0 FAQ

What was Sernova’s price range in the past 12 months?

Sernova lowest stock price was €0.08 and its highest was €0.27 in the past 12 months.

What is Sernova’s market cap?

Sernova’s market cap is C$41.56M.

When is Sernova’s upcoming earnings report date?

Sernova’s upcoming earnings report date is Sep 24, 2025 which is in 53 days.

How were Sernova’s earnings last quarter?

Sernova released its earnings results on Jun 13, 2025. The company reported -€0.006 earnings per share for the quarter, beating the consensus estimate of -€0.013 by €0.007.

Is Sernova overvalued?

According to Wall Street analysts Sernova’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sernova pay dividends?

Sernova does not currently pay dividends.

What is Sernova’s EPS estimate?

Sernova’s EPS estimate is -0.01.

How many shares outstanding does Sernova have?

Sernova has 328,484,770 shares outstanding.

What happened to Sernova’s price movement after its last earnings report?

Sernova reported an EPS of -€0.006 in its last earnings report, beating expectations of -€0.013. Following the earnings report the stock price went down -11.765%.

Which hedge fund is a major shareholder of Sernova?

Currently, no hedge funds are holding shares in DE:PSH0

Sernova Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-67.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.

Sernova (PSH0) Earnings & Revenues

DE:PSH0 Earnings Data >

PSH0 Stock 12 Month Forecast

Average Price Target

€2.09

▲(1639.86%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","-1":"-€1","0.25":"€0.25","1.5":"€1.5","2.75":"€2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.79606044,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€3.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.087833242,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.379606044,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.38</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Sep<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.099,0.3833892646153846,0.6677785292307692,0.9521677938461538,1.2365570584615384,1.5209463230769231,1.8053355876923076,2.0897248523076923,2.374114116923077,2.6585033815384618,2.9428926461538465,3.2272819107692308,3.5116711753846155,{"y":3.79606044,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.099,0.25198717246153846,0.40497434492307693,0.5579615173846153,0.7109486898461538,0.8639358623076923,1.0169230347692306,1.1699102072307692,1.3228973796923076,1.475884552153846,1.6288717246153845,1.781858897076923,1.9348460695384613,{"y":2.087833242,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.099,0.12058508030769231,0.14217016061538462,0.16375524092307692,0.18534032123076924,0.20692540153846156,0.22851048184615386,0.2500955621538462,0.27168064246153845,0.2932657227692308,0.3148508030769231,0.3364358833846154,0.35802096369230774,{"y":0.379606044,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.554,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.491,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.422,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.379,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.233,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.182,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.144,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.12,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.132,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.099,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >